RESVERATROL LIPID BASED NANOPARTICLES SHOW A PROMISING OUTCOME ON INDUCED NON ALCOHOLIC FATTY LIVER DISEASE | ||
| Bulletin of Pharmaceutical Sciences Assiut University | ||
| Volume 46, Issue 2, December 2023, Pages 715-727 PDF (1.41 M) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/bfsa.2023.327652 | ||
| Authors | ||
| Dina Adel Abdelmalek* 1; Basma Nagy Abd-Elhamid1; Noura Hassan Abd Ellah2; Sayed Ismail1 | ||
| 1Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut, Egypt | ||
| 2Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut, Egypt Department of Pharmaceutics, Faculty of Pharmacy, Badr University in Assiut, Naser city, Assiut, Egypt | ||
| Abstract | ||
| Prevalence of nonalcoholic fatty liver disease (NAFLD) affects more than 25% of the populations worldwide. In this study, resveratrol loaded solid lipid nanoparticles (Res-SLNs) were prepared by emulsification and were in vitro evaluated. Res-SLN 1 containing gelucire and tween 80 was selected for further in vitro and in vivo studies. In vivo studies were done via induction of NAFLD in rats with a high fat (HF) diet for 12-weeks followed by a 6-week period of treatment with Res-SLN1. Blood samples and liver sections were taken from rats for biochemical and histological evaluations. Res-SLN1 exhibited high entrapment efficiency (75±22%), small particle size (208±48 nm) and an acceptable release rate. In vivo studies demonstrated a remarkable improvement in lipid profile and liver enzyme with Res-SLN1. The histological features were significantly improved with Res-SLN1. Res-SLNs represent a promising therapeutic approach for NAFLD via prolonging Res release and ameliorating lipid profile and liver enzymes. | ||
| Keywords | ||
| Nonalcoholic fatty liver disease; resveratrol; solid lipid nanoparticles | ||
|
Statistics Article View: 283 PDF Download: 343 |
||
